‘I just had a feeling': Davidson County man wins $100K from $50 scratch-off
'I figured it would happen sooner or later,' said. 'I just had a feeling.'
He purchased an $8 Million Money Maker from the Fast Fuels on Randolph Street in Thomasville.
'I actually wasn't going to go to the store that night because I was feeling a little sick, but I forced myself to go,' he laughed.
Michael was in for a shock when he went home and started scratching his ticket.
'I saw a couple zeroes then another and another,' he recalled. 'I got lucky.'
Michael arrived at lottery headquarters on Wednesday to collect his prize and took home $71,764 after required state and federal tax withholdings.
He plans to use his winnings to build a pier on the lake where he lives.
The $8 Million Money Maker game debuted in December with five $8 million top prizes and 10 $100,000 prizes. Four $8 million prizes and seven $100,000 prizes remain to be claimed.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse ™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. 'This submission represents an important milestone in expanding our Evolysse ™ collection of injectable HA gels,' said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. 'Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics.' Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse ™ Sculpt or Restylane ® -Lyft. The Evolysse ™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse ™ collection. Designed by Symatese using innovative Cold-X ™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ® and Evolysse ™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse ™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse ™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Cold-X ™ and Estyme ® are trademarks of Symatese Group and Symatese Aesthetics S.A.S. Restylane ® is a trademark of Galderma S.A.
Business Wire
27 minutes ago
- Business Wire
Skyworks Sets New Benchmark in Ultra-Low Jitter Clock Buffers for High-Speed Connectivity
IRVINE, Calif.--(BUSINESS WIRE)--Skyworks Solutions, Inc. (Nasdaq: SWKS), a global leader in high-performance analog and mixed-signal semiconductors, today unveiled the SKY53510/80/40 family of clock fanout buffers—designed to meet the stringent timing demands of next-generation high-speed infrastructure. Skyworks Sets New Benchmark in Ultra-Low Jitter Clock Buffers for High-Speed Connectivity Share With the rollout of PCIe Gen 7 and the continued expansion of AI, cloud computing, and 5G/6G networks, timing precision has become a critical enabler of performance. The SKY53510/80/40 family offers a scalable, low-jitter clock buffer solution that simplifies design and enhances signal integrity across a wide range of platforms. For system architects and hardware designers, this means faster time to market, reduced engineering overhead, and the ability to future-proof designs for emerging standards like PCIe Gen 7 and 6G wireless. The SKY53510/80/40 family features a 3:1 input multiplexer (including crystal input), one single-ended output, and up to 10 differential outputs. Offered in compact thermally enhanced QFN packages—7x7mm (10 outputs), 6x6mm (8 outputs), and 5x5mm (4 outputs)—these devices are pin-compatible with industry-standard layouts for easy integration and multi-sourcing. 'Skyworks is pushing the boundaries of clock tree signal integrity,' said James Wilson, vice president and general manager of Mixed Signal Solutions at Skyworks. 'Our new SKY53510/80/40buffer family offers unmatched jitter performance and format flexibility—empowering designers to meet the demands of today's most advanced communication and computing platforms.' Designed for High-Speed Applications SKY53510/80/40 buffers are well suited for: PCIe Gen 3 through Gen 7 56G/112G/224G SerDes 5G/6G mMIMO radio systems SyncE and broadcast video Medical imaging and aerospace/defense These devices support input clock slew rates down to 0.75V/ns and output levels of 1.8V, 2.5V, and 3.3V—enabling robust PCB designs with minimal signal integrity challenges such as reflection, crosstalk, and ground bounce. Key Features The SKY53510/80/40 features include: The devices are ideally suited for pairing with Skyworks' Si551x Network Synchronizers, SKY63104/5/6 family of Jitter Attenuating Clocks and SKY62101 Ultra-low Jitter Clock Generators to deliver complete clock tree solutions that meet the demanding requirements of next-generation 6G wireless infrastructure, 800G/1600G networking infrastructure, and AI data center applications that utilize 112G/224 PAM4 SerDes technology. Availability Samples and production quantities of the SKY53510/80/40 clock buffers are available now. Evaluation is supported via the SKY53510-EVB development kit. For more information, please visit our Any Format Clock Buffers page or contact your Skyworks sales representative. About Skyworks Skyworks Solutions, Inc. is empowering the wireless networking revolution. We are a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables. Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500 ® market index (Nasdaq: SWKS). For more information, please visit Skyworks' website at: Safe Harbor Statement Any forward-looking statements contained in this media alert are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as 'anticipates,' 'expects,' 'forecasts,' 'intends,' 'believes,' 'plans,' 'may,' 'will' or 'continue,' and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties including, but not limited to, our ability to timely and accurately predict market requirements and evolving industry standards and to identify opportunities in new markets; our ability to develop, manufacture, and market innovative products and avoid product obsolescence; our ability to compete in the marketplace and achieve market acceptance of our products; the level of widespread deployment or adoption of commercial 5G networks, AI and other new technologies; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials and supplier components; the quality of our products; our products' ability to perform under stringent operating conditions; and other risks and uncertainties identified in the 'Risk Factors' section of Skyworks' most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission ('SEC'). Copies of Skyworks' SEC filings can be obtained, free of charge, on Skyworks' website ( or at the SEC's website ( Any forward-looking statements contained in this media alert are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.
Business Wire
an hour ago
- Business Wire
Chewy Announces Fiscal Second Quarter 2025 Financial Results Conference Call
PLANTATION, Fla.--(BUSINESS WIRE)--Chewy, Inc. (NYSE: CHWY) ('Chewy'), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal second quarter 2025 financial results before the market opens on Wednesday, September 10, 2025. Management will host a conference call and webcast to discuss the company's financial results at 8:00 am ET. To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call. A live audio webcast can be accessed on the company's investor relations website at and a replay of the conference call will also be available on the company's investor relations website for at least 90 days following the event. Chewy Fiscal Second Quarter 2025 Financial Results Conference Call When: Wednesday, September 10, 2025 Time: 8:00 am ET Live webcast and replay: Conference call registration: Phone Registration Link About Chewy Our mission is to be the most trusted and convenient destination for pet parents and partners everywhere. We believe that we are the preeminent online source for pet products, supplies and prescriptions as a result of our broad selection of high-quality products and services, which we offer at competitive prices and deliver with an exceptional level of care and a personal touch to build brand loyalty and drive repeat purchasing. We seek to continually develop innovative ways for our customers to engage with us, as our websites and mobile applications allow our pet parents to manage their pets' health, wellness, and merchandise needs, while enabling them to conveniently shop for our products. We partner with approximately 3,200 of the best and most trusted brands in the pet industry, and we create and offer our own private brands. Through our websites and mobile applications, we offer our customers approximately 130,000 products and services offerings, to bring what we believe is a high-bar, customer-centric experience to our customers.
